Articles from Adverse Event Reporting News (March 11, 2008)

Title	Author	Type	Words
1 in 10 patients get drug error.			851
Actavis recalls remaining fentanyl patches in the U.S. as precaution.			429
Allergan gets subpoena on Botox promotion.			193
Anemia drugs get black-box warning.			725
Baxter to proceed with recall of remaining heparin sodium vial products.			536
Child studies make drugs safer, researchers say.		Brief article	224
Concerns over Vytorin, Avandia prompt investigation of FDA review process.			713
Draft guidance proposes stricter diabetes drug rules.			888
Drug firms face new laws on test results.			554
FDA cautions on proper use of inhalation medications.		Brief article	202
FDA chief disagrees with administration on budget.			815
FDA isolates heparin contaminant; Germany reports AEs from different brand of blood thinner.			1385
FDA seeking additional data on asthma drugs.		Brief article	235
FDA to boost post-market oversight of drugs.			398
Flu drug makers change labels over behavior issue.			342
Government concedes vaccine injury case.			709
Law not enough to police device maker-doctor ties.			464
Lawmakers agree on offer to view disputed FDA papers.		Brief article	203
Lilly faces initial Zyprexa trial.			522
More than 44,000 enroll in Vioxx settlement.			377
Senator queries FDA and spinal disk maker.			644
Sentinel initiative to gather public, private data on medical product reactions.			1223
Stronger cough medicine warning proposed.		Brief article	222
Too many prescriptions, too few pharmacies.			844
Tysabri's liver warning expanded to MS patients.		Brief article	250
Warnings, advisories on side effects will increase, FDA says.			942
Woodcock named permanent CDER director--again.			387
Wyeth, Upjohn could pay $27 million in HRT case damages.		Brief article	183